Diagnostic Tests and Understanding Lab Reports

Navigating the diagnostic process for Galactosialidosis involves several layers of testing. Because this condition is so rare, a definitive diagnosis requires putting together multiple pieces of a puzzle: what is found in the urine, how enzymes are behaving in the blood or skin, and the specific changes (pathogenic variants) found in the DNA.

Step 1: The Initial Clue (Urinary Screening)

Often, the first sign of a lysosomal disorder comes from a urine test called urinary oligosaccharide screening. In Galactosialidosis, the body cannot break down certain materials, which then spill over into the urine—a condition called sialyloligosacchariduria ^[1][2].

There are two main ways labs look for these materials:

• TLC (Thin-Layer Chromatography): An older, traditional method that has limited sensitivity and can sometimes miss cases ^[3][2].
• LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): A modern, much more sensitive method that can detect subtle patterns TLC might miss ^[2][3].

Step 2: The Functional Test (Enzyme Assays)

If the urine screen or clinical symptoms are suspicious, doctors will order enzyme assays. This test measures how well the cellular “recycling tools” are working, using a dried blood spot, white blood cells (leukocytes), or skin cells (fibroblasts) ^[4][5].

In Galactosialidosis, a typical report will show a “combined deficiency” ^[5]:

• Reduced Beta-galactosidase activity ^[1].
• Reduced Neuraminidase-1 (NEU1) activity ^[5].

Note on Lab Variability: Enzyme activity levels can be affected by the specimen type, transport, the lab’s specific reference ranges, and assay conditions. A result showing only one low enzyme does not automatically mean the diagnosis is wrong; rather, a metabolic laboratory should review the complete report, and repeat or specialized testing may be needed ^[6][7].

Step 3: The Genetic Map (CTSA Testing)

The final step is usually genetic testing of the CTSA gene ^[4]. Galactosialidosis is an autosomal recessive condition. This means a person generally has the disease only if they inherit a “pathogenic variant” (a disease-causing change, formerly called a mutation) from both parents ^[4][P-132]. The parents are typically unaffected carriers. A genetic counselor can discuss what this means for family members and future pregnancies.

Sometimes a genetic report lists a VUS (Variant of Uncertain Significance). A VUS means the lab found a change, but there is not enough evidence to know if it causes disease or is just a harmless natural variation. A VUS cannot be used by itself to confirm or exclude Galactosialidosis. If a VUS is present, a metabolic genetics team must carefully integrate the patient’s symptoms, the enzyme testing, and potentially test the parents (segregation testing) to help interpret it over time ^[8][9].

Understanding Diagnosis Confirmation

Because test results can be complex, a diagnosis of Galactosialidosis is generally confirmed through specialist review of several lines of evidence:

• Biochemical Evidence: Tests interpreted by a specialist laboratory showing reduced activity of both beta-galactosidase and neuraminidase ^[5].
• Genetic Evidence: Identification of two disease-causing variants in the CTSA gene ^[4]. In some cases, a person may have two copies of the exact same variant (homozygous), or specialized testing might be needed to find deletions not seen on standard panels.
• Clinical Picture: Symptoms that match the known patterns of the disease.

If you have questions about your diagnostic reports, ask your metabolic team to walk you through how the biochemical and genetic results line up with your or your child’s symptoms.